Abstract-This paper presents a telemedicine system utilizing an integrated microfluidic chip for fast, automatic detection of insulin. The telemedicine system expedites the insulin assay results digitally from the assay site to medical professionals located off-site, while the off-site specialist can directly provide diagnosis through the Internet. The integrated microfluidic chip contains pneumatic micropumps, a micromixer and several microvalves to automatically perform the entire protocol for insulin detection. The detection protocol is based on double-antibody sandwich chemiluminescence immunoassay. The microfluidic system carries out the detection procedures including sample/reagent transportation, incubation between the target insulin and insulin antibodies, washing processes, and the chemiluminescence development process. The chemiluminescence signal is measured and quantifies the concentration of insulin in the testing sample. Experimental data show that the developed system can automatically complete the entire protocol within 10 min with a detection limit of 260 pmol/L. This microfluidic-based telemedicine system is promising for point-of-care diabetes screening in the future.
INTRODUCTION
Diabetes mellitus is a group of diverse metabolic disorders caused by deficiency or diminished effectiveness of endogenous insulin [1] . At present, blood glucose test is the most popular clinical diagnostic measurement for diabetes, but irregular blood glucose level is not a good early indicator for diabetes diagnosis. Previous studies have shown that insulin and connecting peptide (C-peptide) are better suited as early diagnostic immune indicators for the onset of diabetes [2] . Insulin, a hormone made by the pancreas, is responsible for regulating glucose concentrations in the blood. The abnormity of insulin can be detected as an effective auspice to diagnose diabetes at the early stage. The conventional test methods for insulin in clinical diagnosis, such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and various chemiluminesence based techniques, are usually based on microplates and big automatic biochemistry analyzer. Although these conventional methods are effective, they have several disadvantages, including lengthy assay time, labor-intensive protocol, and poor portability. An easy-to-use testing system for insulin has become increasingly important to public health.
Microfluidic is a promising technique with advantages of low reagent consumption and short analysis time, which is considered to replace the conventional diagnostic systems [3] . In microfluidic systems, sample/reagent transportation, mixing, separation, and detection can be carried out automatically on a single chip [4] . With their portability characteristic, microfluidic systems offer a practical solution to diabetes screening in high risk group of developing country.
Telemedicine, an attractive communication channel for connecting healthcare providers and patients, is formally defined as "the use of medical information exchanged from one site to another via electronic communications" [5] . For diabetic patients, fast serum insulin measurement at home opens a new way to determine the state of the disease within a short period of time, but without timely professional feedback, it has somewhat of a lesser value [6] . Presently, along with the development of cyber technology, telemedicine is changing the existing models for public healthcare particularly in the way of service delivery [7] . Utilizing cyber-based telemedicine, patients living in rural areas can obtain professional diagnosis without leaving their homes [8] . The combination of microfluidic devices and portable detectors capable of transmitting digital information through existing communication channels provides an integrated approach for point-of-care diabetes diagnosis [9] . This paper presents a telemedicine system utilizing an integrated microfluidic chip for fast, automatic detection of insulin. Compared with the microfluidic devices described in our previous publication [10] , the new microfluidic system integrates pneumatic micropumps, a micromixer and several microvalves to automatically perform the entire protocol for insulin detection and significantly decreases the dead volume of the detection system. The developed microfluidic system is controlled both locally and remotely, achieving the goal of local test process under the supervision of remote specialist. The telemedicine system expedites the insulin assay results digitally from the assay site to medical professionals located off-site, while the off-site specialist can directly provide diagnosis through the Internet.
II. TELEMEDICINE SYSTEM DESIGN
The primary components of the proposed telemedicine system include a local microfluidic system for insulin detection, and a wireless communication device such as a cellphone or PC (Fig. 1 ). In the local microfluidic system, an integrated PDMS-based microfluidic chip carries out the immune reactions of insulin detection automatically with a control system and a chemiluminescence detector. A wireless communication device conveys the control parameters and test results through the Internet, and these results are displayed on the monitor of the diabetes specialist's computer. The role of the off-site specialists would be to analyze the data and to offer professional opinion. After receiving and analyzing the test result, the physician remotely adjusts the control parameters of the microfluidic system when necessary. 
III. MATERIALS AND METHODS

A. Experimental Procedure
The detection protocol is based on double-antibody sandwich chemiluminescence immunoassay. Fig. 2 shows a schematic illustration of the experimental procedure for insulin detection using chemiluminescence immunoassay based on magnetic microbeads. First, the paramagnetic beads covalently coupled with monoclonal insulin antibodies are mixed with bio-samples for insulin incubation (Fig. 2a) . After the incubation process, the target insulin molecules in samples are recognized and adhere onto the magnetic microbeads to form a half sandwich structure. The magnetic-bead complex is attracted onto the bottom using an external magnet, and the non-reactive interference substances are washed out (Fig. 2b) . Then, the insulin antibodies labeled with acridinium ester are mixed with the half sandwich structure for incubation to form the whole sandwich structure (Fig. 2c) . Again, any non-conjugated acridinium ester-labeled insulin antibodies are washed out when the external magnetic field is applied (Fig. 2d) . Suspending sandwich structure microbeads in developing solution 1 (3% H2O2 solution containing 0.1N HNO 3 ) and developing solution 2 (1.5N NaOH solution containing 2% TritonX-100) is injected, and light is emitted rapidly (Fig.  2e) . The light intensity can be quantified by an optical detector. A direct relationship exists between the amount of insulin present in the test sample and the light intensity detected by the chemiluminescence detector. The entire insulin detection process, including reagent transportation, incubation of the target insulin and insulin antibodies, washing, and the chemiluminescence development process, is automatically performed by a single integrated microfluidic chip.
B. Integrated Microfluidic System
A schematic illustration of the microfluidic chip is shown in Fig. 3a . The integrated microfluidic chip is composed of four pneumatic micropumps, five microvalves and one micromixer. In order to precisely and rapidly transport the reagents, the pneumatic micropumps and the normally closed microvalves are integrated into the microfluidic chip. The microfluidic chip has four inlets and one outlet for transporting fluids. The exploded view of the microfluidic chip is showed in Fig. 3b . The chip consists of one glass substrate (500 m thick) and two separate PDMS layers: a liquid microchannel layer (about 5mm thick) and a pneumatic air chamber layer (about 300 m thick). The liquid channel layer is used for connecting six fluidic chambers (including four inlets, a mixing chamber, and an outlet for waste), normally closed microvalves and microchannels. The air chamber layer consists of several membrane-enclosed air chambers for the micropumps, the micromixer and the microvalves. The thickness of the pneumatic membrane in the air chamber PDMS layer is approximately 100 m. A photograph of the assembled microchip is shown in Fig. 3c , and the overall dimensions of the chip are measured to be 38mm by 48mm. In the local microfluidic system, an integrated PDMS-based microfluidic chip is connected to a control system and a chemiluminescence detector (Fig. 4) . The control system consists of a mini air compressor, an air pressure sensor, a rectangular pulse generator, electromagnetic valves (EMVs), a permanent magnet controlled by electromagnet, a unit motor, and a Samsung S3C2440 embedded processor. Externally generated compressed air is injected into the air chambers of the micropump and micromixer to individually actuate them. In order to regulate the performance of magnetic beads during the mixing and washing process, the permanent magnet is controlled by electromagnet automatically. The unit motor is used to adjust the position of the microfluidic chip between the original location for immune process and the location above the photomultiplier tube (PMT). PMT is an optical detection to measure the luminous intensity of the chemiluminescence immunoassay in the microfluidic system, and the shell of the local microfluidic system should be opaque to protect the sensitivity of PMT and reduce the noise level.
The microfluidic chip is first placed in the location for immune process, where the magnet can be added to the mixer area to attract the beads during the washing process. After the immune process, the chip is moved to the location above the PMT in order to detect the chemiluminescence signal when the developing solution is injected. The Samsung S3C2440 embedded processor is a highly integrated chip with ARM920T core, and suitable for WIFI wireless local area network communication. 
IV. EXPERIMENTAL RESULTS
A. Automatic Detection of Insulin Concentration
Automatic detection of insulin concentration is carried out by using the local microfluidic system. 5 demonstrates the variation of chemiluminescent light intensity with time during the chemiluminescence reaction process in the micromixer. The light is generated within a short period of time. After reaching a peak value, the light signal starts to decline back to the baseline. The peak value is used here to represent the concentration of insulin. To detect the insulin concentration automatically, the time-varying luminous intensity is digitized and the result is further processed to determine the peak value directly. Instead of the complete light-intensity curve, only information related to the insulin concentration is shown to both the local and off-site. 
B. Insulin Sensitivity and Calibration
In order to verify the performance of the microfluidic based telemedicine system, different concentrations of insulin samples are tested in the proposed system. Fig. 6 shows the calibration curve of the insulin immunoassay in the microfluidic chip, demonstrating the relationship between the intensity of the emit light in RLU and the insulin concentration. As indicated by the figure, the insulin detection limit of the microfluidic system is about 260 pmol/L. The insulin concentration forms a relatively linear relationship with the chemiluminescent light intensity between 260 pmol/L and 1570 pmol/L. The entire detection time is about 10 minutes, which is much faster than that of the conventional methods for insulin detection. It is envisioned that a parallel microfluidic system consisting of highly integrated micropumps and micromixers can be developed to save even more time. 
V. CONCLUSIONS AND FUTURE WORKS
A cyber-based telemedicine system for insulin measurement using an integrated PDMS microfluidic chip has been demonstrated. Through the Internet, this detection method provides a new technique for diabetes screening by supporting real-time diagnostics. The integrated microfluidic chip contains pneumatic micropumps, a micromixer and several microvalves, and the complete insulin detection process is accomplished in the chip. Based on double-antibody sandwich chemiluminescence immunoassay, the insulin detection limit is determined to be 260pmol/L, with a linear range between 260pmol/L and 1570pmol/L. The entire detection time in the microfluidic system is about 10 minutes. When compared to the conventional methods, this microfluidic based telemedicine system is promising for conducting large-scale diabetes diagnosis for the general population. Further studies will be carried out to validate these designs and to promote telemedicine as an opportunity for point-of-care diabetes screening.
